Aisling Capital LLC This is a life science investment firm that focuses on investing on companies that manufacture and sell innovative healthcare products, services, and technologies. The firm submitted its SEC 13F Filings on November 14, 2014, for the financial quarter ended September 30, 2014. The filings show that Versartis Inc (NASDAQ:VSAR), Transenterix Inc (NYSEMKT:TRXC), and Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) are the top three holdings of Aisling Capital LLC.
Versartis Inc (NASDAQ:VSAR) emerged as the topmost investment of Aisling Capital LLC. The investment amounted to a total of $55.1 million in value. Versartis Inc (NASDAQ:VSAR) is a company that develops therapeutic proteins for the treatment of endocrine disorders and metabolic diseases. The company reported a net loss of approximately $13.8 million for the third quarter ended September 30 this year, which is attributable to common stockholders. The company has however made some milestones this year. The company finished the design of the VRS-317 Phase 3 clinical trial for pediatric GHD patients after holding discussion with the FDA and EMA. The company will also be carrying out series of clinical tests in Western Europe and Canada in 2015. The company’s top three biggest institutional shareholders are Aisling Capital LLC, RA Capital Management, LLC, and Baker Bros Advisors LLC.
The filings indicated that Transenterix Inc (NYSEMKT:TRXC) was the second largest investment of the firm with investment valued at $42 million. Transenterix Inc (NYSEMKT:TRXC) is a medical device company that carries out surgical operations using flexible instruments and robotics to enhance precision and improve results of minimally invasive surgery. The company reported its quarterly results on November 6, posting $0.18 in earnings per share, which was the same as the consensus estimate of Thomson Reuters. The top three shareholders of the company are Aisling Capital LLC, SV Life Sciences Advisers LLC, and Synergy Life Science Partners LLC.
Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) was the third biggest investment of Aisling Capital LLC with investment value of $39.5 million. Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) is a company that provides medical services, focusing on the design, development, and sale of non-invasive procedures for the reduction of stubborn fat bulges that may not be reduced through diet or physical exercise. Deloitte’s 2014 Technology Fast 500(TM) recently ranked Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) as the fastest growing medical device company in North America. The ranking encompasses companies in the media, technology, telecommunications, clean technology, and life sciences industries.
This article has been written by Victor Ochieng.
The 10 Biggest Tea Drinking Countries in the World